Key Highlights

  • Black Hawk Acquisition (NASDAQ:BKHA) was trading up 22.79% at USD 6.60 in pre-market on Friday, November 13, 2026, per pre-market market data. Calculated arithmetic implies a prior close of about USD 5.38.
  • Shareholders approved the Business combination with Vesicor Therapeutics at a meeting on October 13, 2026, and about 2.09 million shares were redeemed for roughly USD 25.2 million, per a published summary of the filing.
  • Vesicor was valued at USD 70 million pre-money in the April 2025 agreement, which required Vesicor to secure at least USD 10 million of transaction financing and carried a USD 1 million break-up fee.
  • Cash was about USD 12 thousand in the latest quarterly report, with a Working Capital Deficit near USD 2.3 million and a formal Going Concern qualification.

A SPAC Move With No Dated Announcement

Black Hawk Acquisition (NASDAQ:BKHA), a blank-check company, was trading up 22.79% at USD 6.60 in pre-market on Friday, November 13, 2026. No company announcement explaining the move was found for November 11 to November 13. A calculated prior close of about USD 5.38 implies a gain of USD 1.22. Prices of special purpose acquisition shares can behave oddly after a vote, when most remaining holders are arbitrage funds, trading is thin and a small order can shift the quote. Whether the Merger has closed, and whether the ticker has changed, was not confirmed.

The Vesicor Therapeutics Merger Terms and Vote

Black Hawk signed a definitive agreement with Vesicor Therapeutics on April 26, 2025. Black Hawk is to domesticate as a Delaware corporation, a Subsidiary will merge into Vesicor, and the combined company is to take the Vesicor Therapeutics name. At the October 13, 2026 Shareholder meeting all proposals passed, and redemptions of about 2.09 million shares withdrew roughly USD 25.2 million from the trust, which implies about USD 12.04 per share. That Redemption price conflicts with a USD 10.05 trust value in another summary, so both figures are flagged as unverified and drawn from AI-generated summaries.

Going Concern Doubt, Financing and the December Deadline

The most recent Quarterly Report cites cash of about USD 12 thousand, a working capital deficit near USD 2.3 million and substantial doubt about continuing as a going concern. Funding includes USD 1.5 million of convertible notes at USD 1.00 per share and a USD 200 million standby Equity purchase agreement with Meteora, along with forward purchase and non-redemption agreements. A failure to close by the December 2026 deadline would force liquidation, according to a published summary. Nasdaq compliance on Market Value of listed securities was regained in August 2026. Dilution from the equity line and thin float are the main risks.

Where Things Stand

Possibly, but only if the deal closes on time and the stock stays tied to it. No announcement explaining the 22.79% pre-market gain at Black Hawk Acquisition (NASDAQ:BKHA) was found. Shareholders approved the Vesicor merger on October 13, 2026, and the remaining steps are closing, the Delaware domestication, any ticker change and the financing Vesicor must secure. Going concern doubt, a USD 12 thousand cash balance and the December 2026 deadline add risk. Watch for a closing 8-K, the new trading symbol and post-merger share count. Any figure from the summaries should be checked against filings, because the summaries note that they may contain numerical errors. Holders weighing the stock should also remember that a SPAC share price is anchored to trust value only until the merger closes.